Which company's product is Rucaparib?

Rucaparib was developed byClovis Oncology until it was sold to Pharmand GmbH (Pharma&) as part of the Clovis bankruptcy proceedings. In December 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the treatment of advanced ovarian cancer cases. It was approved for medical use in the European Union in May 2018 and was designated as an orphan drug, designed to treat recurrent or progressive ovarian cancer.

Rucaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy, and for the treatment of adult patients with deleterious BRCA mutation-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapy regimens. Rucaparib is also indicated for the treatment of adult patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor-directed therapy and taxane-based chemotherapy.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).